Skip to main content
. 2024 Jul 17;12(7):784. doi: 10.3390/vaccines12070784

Table 2.

Median values of anti-RBD IgG and IFN-γ, GMTs of BA.5 nAbs according to study groups across all the time points (only for available samples).

Total
(n = 231)		 NoC
(n = 72)		 BTIs
(n = 56)		 H
(n = 103)		 p-Value * BTIs vs. NoC
p-Value		 * H vs.
NoC
p-Value		 * H vs.
BTIs
p-Value
Anti-RBD IgG T0 212.7
(5.9–979.0)		 46.5
(2.5–815.8)		 26.1
(1.4–360.5)		 474.1
(105.1–1607.5)		 <0.001 <0.001 <0.001
Anti-RBD IgG T1 1589.1
(1147.2–2485.3)		 1497.6
(1112.1–2053.1)		 1265.5
(959.4–2677.6)		 1833.2
(1245.2–2652.7)		 0.174
Anti-RBD IgG T2 666.0
(478.6–1166.7)		 640.5
(397.9–790.4)		 622.5
(415.1–1322.2)		 802.0
(539.9–1283.2)		 0.083
Anti-RBD IgG T3 277.8
(182.2–459.1)		 224.3
(163.2–337.1)		 295.5
(197.7–862.3)		 295.1
(190.9–393.2)		 0.378
Anti-RBD IgG T4 80.9
(60.9–432.5)		 118.6
(26.1–961.9)		 141.1
(64.5–432.5)		 63.7
(33.2–69.4)		 0.366
BA.5 nAbs T0 8.7
(7.2–10.5)		 6.3
(5.1–7.7)		 5.6
(4.7–6.7)		 14.8
(9.9–22.03)		 <0.001 <0.001 <0.001
BA.5 nAbs T1 19.2
(15.9–23.1)		 14.1
(11.0–18.1)		 22.2
(14.3–34.5)		 21.2
(16.2–27.8)		 0.183
BA.5 nAbs T2 9.6
(7.7–12.0)		 5.6
(5.1–6.3)		 13.4
(7.7–23.4)		 11.7
(8.2–16.7)		 0.002 0.006 0.002
BA.5 nAbs T3 8.7
(6.3–12.1)		 5.2
(4.8–5.6)		 17.4
(8.9–33.7)		 5.0
(5.0–5.0)		 <0.001 <0.001 0.002
IFN-γ T0 38.2
(7.0–204.4)		 27.5
(4.0–140.0)		 26.8
(1.5–180.4)		 92.0
(16.1–343.4)		 0.039 0.014
IFN-γ T1 95.0
(14.5–242.5)		 52.3
(15.0–183.0)		 112.8
(4.0–351.8)		 106.3
(22.4–186.4)		 0.554
IFN-γ T2 66.2
(5.2–191.2)		 47.2
(3.6–131.3)		 79.5
(0.3–237.0)		 119.2
(14.1–282.5)		 0.200
IFN-γ T3 121.8
(41.1–367.8)		 25.7
(2.8–133.7)		 103.1
(29.1–697.5)		 176.3
(100.3–398.9)		 0.212
IFN-γ T4 589.0
(216.5–728.5)		 216.5
(216.5–216.5)		 589.0
(589.0–589.0)		 728.5
(728.5–728.5)		 0.367

Data are expressed as the median and interquartile range (IQR); * p-value < α/3 for Bonferroni multiple testing correction.